Edgar Filing: DUSA PHARMACEUTICALS INC - Form 25-NSE

DUSA PHARMACEUTICALS INC

Form 25-NSE December 20, 2012

arset=US-ASCII">

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB APPROVAL		
					3235-0287		
Check this box if no longer				Expires:	January 31, 2005		
subject to Section 16. Form 4 or Form 5 obligations may continue.	Exchange Act of 1934, y Act of 1935 or Section	Estimated average Act of 1934, of 1935 or Section					
See Instruction 1(b).	30(11) of the Investment Company Ac	7 OI 17 10				
(Print or Type Respon	ses)						
Name and Address Sampson Richard	of Reporting Person * A	2. Issuer Name and Ticker or Tradi Symbol	ng 5. Relationship of Issuer	elationship of Reporting Person(s) to er			
		ATMOS ENERGY CORP [A	ΓO] (Checl	(Check all applicable)			
(Last) (I	First) (Middle)	3. Date of Earliest Transaction					
5340 LBJ FREEWAY, 1800 III LINCOLN CENTRE		(Month/Day/Year) 03/06/2015	X Director Officer (give below)	Officer (give title Other (spe			
(S	treet)	4. If Amendment, Date Original Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by C	_X_ Form filed by One Reporting Person			
DALLAS, TX 75	240		Form filed by M Person	fore than One Ro	eporting		
(City) (S	(Zip)	Table I - Non-Derivative Secur	rities Acquired, Disposed of	, or Beneficia	lly Owned		
	nsaction Date 2A. Deer h/Day/Year) Execution any (Month/I		r Securities For Beneficially (I Owned (I	Ownership orm: Direct O) or Indirect) nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Transaction(s)

(Instr. 3 and 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

or

Code V Amount (D) Price

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 25-NSE

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Code	5. Number for Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerc Expiration Day/ (Month/Day/	Date	7. Title and A Underlying S (Instr. 3 and 4	Securities	8. Pric Deriva Securi (Instr.
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Phantom Stock Units	<u>(1)</u>	03/06/2015	A	3,000	(2)	(2)	Common Stock	3,000	\$ 52

Reporting Owners

Reporting Owner Name / Address	Relationships				
r g	Director	10% Owner	Officer	Other	
Sampson Richard A 5340 LBJ FREEWAY 1800 III LINCOLN CENTRE DALLAS, TX 75240	X				
0:					

Signatures

/s/Suzanne Johnson
by POA

**Signature of Reporting

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each unit of phantom stock is equivalent to one share of the Company's common stock.
- (2) The phantom stock units were granted under the 1998 Long-Term Incentive Plan (the "Plan") and are to be settled upon the reporting person's termination of service on the Company's Board.
- (3) Includes 183.75 phantom stock units resulting from a dividend reinvestment feature of the Plan which were allocated to reporting person's account since March 10, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2